Clinical trials
catalyst calendar across sponsors →Studies where SION is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 9 tracked-famous managers (VIKING GLOBAL INVESTORS LP, CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, Artisan Partners Limited Partnership, Qube Research & Technologies Ltd, +4 more) · FINRA short interest 6.8 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to TrikaftaNCT07108153To evaluate the incidence of treatment emergent adverse events [Safety and Tolerability] when SION-719 is administered to people with cystic fibrosis (CF) who are taking a standard stable dose of physician-prescribed TrikaftaRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: SION-719, Placebo-to-match SION-719 | Cystic Fibrosis (CF) | 16 | Jul 2026 | 2026-05-06 |
| Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.NCT07035990To evaluate the incidence of treatment emergent adverse events [Safety and Tolerability] of SION-451 and SION-109 when administered in combination to healthy participantsRandomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: SION-451, SION-2222, SION-109, Placebo SION-451, Placebo SION-2222, Placebo SION-109 | Cystic Fibrosis (CF) | 144 | Jun 2026 | 2025-09-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19